Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGs

Status Not yet recruiting

Clinical Trial Summary

When a newborn is diagnosed with tachyarrhythmia, they are generally started on medical therapies, most commonly a beta-blocker, while being observed in an inpatient setting. In most academic institutions, current practice is to provide parental teaching on use of a stethoscope to auscultate their child when there is suspicion for distress, in addition to requiring cardiopulmonary resuscitation (CPR) classes. Fortunately, newer technologies have emerged that allow for capture of cardiac rhythm that may provide a buffer between the infant and the emergency room.

Clinical Trial Description

Tachyarrhythmias which would prompt an emergent call to the pediatric cardiologist following the child, along with simultaneous transportation towards the nearest, preferably pediatric, emergency room. In reality, parental caregivers may be blinded by their personal anxiety in caring for their child with a tachyarrhythmia, and their interpretation or ability to count their child's heart beats may not be accurate. This in turn, can result in unnecessary calls and visits to the emergency room which increase their utilization in addition to piling onto the already astounding cost of healthcare in the United States. Fortunately, newer technologies have emerged that allow for capture of cardiac rhythm that may provide a buffer between the infant and the emergency room. Eko manufactures a digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time. Currently, the DUO is cleared for use on patients greater than or equal to 10 kg. This device may have additional clinical utility in pediatric patients <10 kg when used by either a physician or a parent/caregiver at home for remote patient monitoring. The CORE 500 may also have clinical utility in this patient population. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06382207
Study type	Interventional
Source	Virginia Commonwealth University
Contact	Christopher Snyder
Phone	8046284787
Email	christopher.snyder@vcuhealth.org
Status	Not yet recruiting
Phase	N/A
Start date	May 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02565238` - BIO.MASTER.BioMonitor 2 Study	N/A
Completed	`NCT02849769` - Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study
Completed	`NCT04025710` - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)	N/A
Active, not recruiting	`NCT05621187` - Post Market Clinical Follow-up Study for the Pamira ICD Lead Family	N/A
Active, not recruiting	`NCT01526629` - Full Automaticity and Remote Follow-up	N/A
Completed	`NCT03850327` - BIO\|CONCEPT.BIOMONITOR III	N/A
Recruiting	`NCT04905199` - Temporary Transvenous Pacemaker Placement by Intracavitary Electrocardiogram Monitoring
Completed	`NCT03408951` - Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment
Not yet recruiting	`NCT06327425` - MCG for Localization of Tachyarrhythmia's Origin	N/A
Recruiting	`NCT04863664` - Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)	N/A
Not yet recruiting	`NCT05750108` - Transcutaneous Vagal Nerve Stimulation to Prevent Tachyarrhythmias in Patients Early Following Myocardial Infarction	N/A
Completed	`NCT02774616` - BIO\|MASTER.Ilivia Family / Plexa	N/A
Completed	`NCT00231426` - ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations	Phase 4
Completed	`NCT02181686` - Iperia/Sentus QP Study	N/A
Terminated	`NCT03451227` - Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures	N/A
Completed	`NCT02933619` - ProMRI ICD/CRT-D Post Approval Study
Completed	`NCT00324662` - Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA)	Phase 4
Completed	`NCT00170274` - APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias	N/A
Completed	`NCT03891329` - Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead	N/A
Completed	`NCT06323499` - Outcome of Induced Atypical Atrial Flutter

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.